REM-HF: Remote Monitoring in Patients With Heart Failure
Study Details
Study Description
Brief Summary
This study is a prospective cohort study with consecutive enrollment of newly diagnosed heart failure patients, investigating the prevalence and types of arrhythmias in this high-risk population using non-invasive remote monitoring with the Coala Heart Monitor. Participants are scheduled to use the Coala Heart Monitor twice daily or during symptoms (e.g. syncope, presyncope, palpitations, chest discomfort, or shortness of breath) to record a thumb and chest ECG over 3 months. Patient compliance with the recordings, self-reported health, response to technology, and experience using the device will additionally be assessed by self-developed questionnaires and the Kansas City Cardiomyopathy Questionnaire (KCCQ) at 3 months.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Outcome Measures
Primary Outcome Measures
- New-onset arrhythmias [3 months]
Incidence of newly diagnosed atrial fibrillation/atrial arrhythmias on patient-activated thumb and chest ECG recordings
Secondary Outcome Measures
- Patient compliance [Week 8]
Patient compliance with at least two daily recordings.
- Patient self-reported health [3 months]
Patient self-reported health assessed by KCCQ.
- Patient-reported outcomes [3 months]
Patients' response to technology and experience using the device assessed by self-developed questionnaire.
- Assessing recordings [3 months]
Where there are interpretations of arrhythmias on recordings, agreement of recordings with subsequent Holter monitoring will be assessed.
- Subsequent prescriptions [3 years]
Through linkage with nationwide health care databases, subsequent prescription patterns of diuretics and antithrombotic medication in patients with and without atrial fibrillation.
- Subsequent implantations [3 years]
Through linkage with nationwide health care databases, subsequent implantation of cardiac devices in patients with and without atrial fibrillation.
- Subsequent readmissions [3 years]
Through linkage with nationwide health care databases, subsequent readmissions to hospital in patients with and without atrial fibrillation.
- All-cause mortality [3 years]
Through linkage with nationwide health care databases, all-cause mortality in patients with and without atrial fibrillation.
- Cardiovascular mortality [3 years]
Through linkage with nationwide health care databases, cardiovascular mortality in patients with and without atrial fibrillation.
- Admissions for worsening heart failure [3 years]
Through linkage with nationwide health care databases, and admission for worsening heart failure in patients with and without atrial fibrillation.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Owns or has access to a smartphone
-
Newly diagnosed moderate to severe heart failure (NYHA II-IV and left ventricular ejection fraction ≤ 40%)
Exclusion Criteria:
-
Earlier atrial fibrillation/atrial flutter with indication for oral anticoagulant (OAC) treatment
-
Pacemaker
-
Cardiac resynchronization device
-
Indications for OAC treatment (also low molecular weight heparin) due to atrial arrhythmias, mechanical heart valve, deep vein thrombosis, or pulmonary embolism.
-
Expected survival ≤ 6 months
-
Absolute contraindications for starting OAC treatment
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Department of Cardiology, Herlev & Gentofte Hospital | Copenhagen | Hellerup | Denmark | 2900 |
Sponsors and Collaborators
- Herlev and Gentofte Hospital
- Coala Life, Inc
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- P-2020-551